In comparison to past reports, more patients in our study achieved an AHI < 5 using an aOA. The aOA is comparable to CPAP for patients with mild disease, while CPAP is superior for patients with moderate to severe disease. A lower AHI was the only predictor of a successful aOA titration.
Introduction:
An oral appliance (OA) is a device that fits within the oral cavity and prevents upper airway collapse in patients with obstructive sleep apnea syndrome (OSAS). A recent American Academy of Sleep Medicine (AASM) guideline concluded that OAs are less effective than continuous positive airway pressure (CPAP), but are a reasonable alternative for patients with mild-to-moderate obstructive sleep apnea (OSA) in specific situations. 1, 2 For patients with severe
OSA, a trial of CPAP is required prior to their use, and surgery may be preferred over an OA for CPAP failures. Predicting which patients will have a successful OA titration and treatment response is difficult.
1,2
The studies used to establish these guidelines are limited by small sample sizes, select patient populations, and the absence of device titration during polysomnography (PSG). The two largest trials enrolled only 256 19 and 263 18 patients. Trials included patients who failed or had a contraindication to CPAP, 18, 22, 23 which may bias the results toward a less responsive population.
Most study protocols for performing a PSG with an OA in place did not include active titration during the study. 8, 18, 24 Given these limitations, the published data likely underestimates the efficacy of an OA and leaves clinicians uncertain as to which patients might benefit from their use.
At the Walter Reed Army Medical Center (WRAMC) sleep clinic, an adjustable OA (aOA) is often ordered for patients who are set to deploy, even if they are already using CPAP.
This provides an opportunity to study a large patient population not biased by a high proportion of CPAP failures. In addition, all patients have their aOA setting optimized by titration during
PSG. We sought to analyze data from patients prescribed an aOA by our clinic to clarify their role in the treatment of OSAS, with the expectation that our success rate would be higher than previously published estimates.
Methods:
Patients All patients diagnosed with the OSAS at our institution undergo education regarding the health effects of untreated OSA and the need for adequate therapy. Whether they are prescribed CPAP, an OA, or both, they are trained in the proper care for and maintenance of their device(s).
We provide serial clinical evaluations after therapy is initiated, where methods to maximize adherence are discussed. When applicable, active sinus disease is adequately treated prior to initiating OA therapy.
Oral Appliance
All patients received a Thorton Adjustable Positioner (Airway Management, Inc., Dallas, TX), an aOA designed for PSG titration and used for the treatment of snoring and OSAS. The
Thorton Adjustable Positioner (TAP) is a custom made, two-piece appliance which fits over the upper and lower teeth. It aims to prevent the tongue and soft tissues of the throat from collapsing into the airway by forward protrusion of the lower jaw. The TAP has an anterior dial which allows adjustment to achieve maximum comfort and efficacy. Each turn is equal to 0.25 mm of additional jaw protrusion.
After being diagnosed with OSAS, patients were followed by a board-certified sleep medicine physician. They were referred to one of two dentists, each specifically trained in sleep medicine, to be fitted for an individually customized device. After the maximum mandibular protrusion (MMP) was estimated, the dentist then fit the appliance, instructed the patient on how to adjust and care for the device, and counseled the patient on side effects. The initial setting was usually at 70-80% of the MMP.
After being fitted, patients began an at-home adjustment protocol with the aOA set in a neutral position. Patients were instructed to advance the device 0.25mm (1 turn) each night as tolerated, with the goal of optimizing subjective sleep quality. In the event of discomfort, the device was regressed 0.5 mm (2 turns) and subsequent advancement was resumed at a slower pace. Using the setting that the patient settled on during the at-home titration protocol and the patient's sleep diary, the degree of mandibular advancement that optimized sleep quality was estimated.
Follow-up PSG with aOA titration was scheduled after subjective improvement in sleep quality. At follow-up PSG, the aOA was set to 1 mm of mandibular advancement less than the number of turns used at home, and incrementally advanced to eliminate respiratory events (apneas, hypopneas, and snoring). If the patient was uncomfortable at a given number of turns, the technician was instructed to dial back two turns and to cease advancing the device for the remainder of the study. Technicians were instructed not to advance the device past the MMP.
After their titration PSG, patients used the number of turns that provided the lowest AHI, provided side effects were tolerable.
Polysomnography
The diagnosis of OSA was made by an attended, overnight level I polysomnogram in all subjects. The apnea-hypopnea index (AHI) was used to define the severity of OSA in accordance with the American Academy of Sleep Medicine (AASM) criteria, as follows: Hypopneas were defined by the AASM alternative criteria. 26 For the overnight CPAP titration on PSG, patients were titrated according to AASM guidelines. 27 All PSGs were scored by a certified sleep technician in accordance with the published AASM guidelines, 26 and interpreted by a board-certified sleep physician. Relevant PSG data were abstracted, including oxygen saturation nadir, total time with oxygen saturation less than ninety percent, and AHI in both the supine and lateral positions. Patients were labeled as having "positional" sleep apnea if the AHI in the lateral position was < 5 and was 50% lower than that seen in the supine position. For aOA titration studies, the time, AHI, and amount of REM sleep at the maximum number of turns were recorded. For CPAP titration studies, the final pressure and the AHI at that pressure were recorded.
Treatment Success
Because a CPAP titration is considered unsuccessful unless an AHI < 5 is achieved, 27 we used an AHI < 5 as our criteria for success when we compared the aOA to CPAP. Many OA studies cited in the AASM practice guideline used an AHI < 10 0.97-0.99; p=0.002).
Discussion
We found that the majority of patients using an aOA achieved an AHI < 5 on the PSG titration, and the ESS decreased significantly after an aOA was prescribed. In multivariate analysis, only AHI remained a significant predictor of aOA success. Although CPAP was superior for patients with severe OSA, the difference in AHI reduction between the aOA and CPAP was not significant for patients with mild and moderate disease.
In comparison to previous studies, the OA success rate at our clinic was higher. The AASM Guidelines 1,2 and a recent review 32 both quote a summary success rate from the literature, using AHI < 10, of just over 50%. Our population's success rate using the same criteria was 73.6%. The largest studies performed to date quote success rates of 54% 18,19 51%, 8 and 49.1% 28 using an AHI < 10, and 36% 24 using an AHI < 5 as the definition for success, all considerably lower than our rates. Our success rate for patients with severe disease was also higher than previously seen. All of the variables identified as predictors in our univariate analysis have been cited in the literature before. 1, 32 Evaluations of predictors performed by different investigators have varied based on the outcomes predicted, the definitions used for positional apnea, the type of analysis performed (linear versus logistic regression), and whether or not cephalometric and other variables were included in the models. 8, 11, 18, [35] [36] [37] [38] This makes comparisons difficult, and the lack of prospective validation limits the inferences that can be made from the existing data on predictors of success.
We cannot determine with certainty why our aOA success rates were higher than those seen previously, but we believe there are two possible reasons. First, our patients had their aOAs titrated during the follow-up PSG, which is a relatively new technique that is only briefly 18, 38 Even for those studies that did not explicitly state whether patients failed CPAP prior to using an OA, given the guidelines, it is reasonable to assume that a portion of the patients enrolled had tried and failed CPAP. Because many of the patients seen at our clinic had not failed CPAP when their OA was prescribed, our population was not subject to the same degree of selection bias.
Our study has several limitations. Because it was retrospective, we were not able to collect variables that others found predictive of OA success, to include the maximum jaw protrusion and the cephalometric analysis that was done at the initial dental visit. Our population includes a large portion of active duty Military members, so our findings may not generalize to a civilian population with different demographics and anthropomorphic features. While the long time interval between diagnostic PSG and aOA titration likely reflects issues with timely access to dental care and PSG wait times, if the patient lost weight during this period or made additional adjustments to their treatment, this could bias our results towards a better aOA titration. We also have no data on side effects, treatment preferences, adherence, or clinical failures, so it is not possible to perform a risk-benefit analysis for aOA therapy.
In summary, in the largest patient population studied to date, we found a higher aOA success rate than previously seen. Based on our results, an aOA would be a reasonable, first-line alternative to CPAP for patients with mild disease. For patients with moderate to severe disease, our higher success rates call into question the recommendation that a CPAP failure is required prior to using an adjustable OA. Future studies should focus on measuring aOA adherence and side effects along with patient treatment preferences so that a comprehensive comparison to CPAP can be conducted.
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